Compare SGHT & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHT | NAUT |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 395.5M | 245.0M |
| IPO Year | 2021 | N/A |
| Metric | SGHT | NAUT |
|---|---|---|
| Price | $6.54 | $2.00 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.23 | N/A |
| AVG Volume (30 Days) | ★ 340.7K | 217.3K |
| Earning Date | 03-04-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $76,052,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.03 | $0.62 |
| 52 Week High | $9.24 | $2.54 |
| Indicator | SGHT | NAUT |
|---|---|---|
| Relative Strength Index (RSI) | 34.11 | 52.48 |
| Support Level | $6.39 | $1.89 |
| Resistance Level | $7.55 | $2.29 |
| Average True Range (ATR) | 0.56 | 0.14 |
| MACD | -0.20 | -0.01 |
| Stochastic Oscillator | 3.85 | 47.21 |
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.